Fred Hutch Expert Available to Discuss NEJM Article on Biomarker Tests for Molecularly Targeted Therapies
Fred Hutchinson Cancer CenterGary H. Lyman, MD, MPH, an internationally recognized oncologist and health economist at Fred Hutchinson Cancer Research Center and a member of a committee of the National Academies of Sciences, Engineering, and Medicine (NASEM), is available to discuss biomarker tests for molecularly targeted therapies. Earlier this month he co-authored a New England Journal of Medicine “Perspective” article summarizing the recommendations for biomarker tests, considered “the key to unlocking precision medicine.” These biomarker tests are very important as more and more tests become available to consumers, and both physicians and patients need to be sure the test they are taking is useful and of value specifically to them.